GSK: Nucala approved in Japan for rhinosinusitis
(CercleFinance.com) - GSK announces that the Japanese Ministry of Health has approved Nucala (mepolizumab) for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) in adults whose symptoms are not controlled by standard therapies.
This approval is based on Phase III clinical trials demonstrating the drug's efficacy and safety.
CRSwNP is a chronic disease affecting 1%-4% of the population, with 40% of cases uncontrolled. The company says that Nucala will offer an alternative to surgery and systemic steroids for these patients.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
This approval is based on Phase III clinical trials demonstrating the drug's efficacy and safety.
CRSwNP is a chronic disease affecting 1%-4% of the population, with 40% of cases uncontrolled. The company says that Nucala will offer an alternative to surgery and systemic steroids for these patients.
Copyright (c) 2024 CercleFinance.com. All rights reserved.